<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nirogacestat: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nirogacestat: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nirogacestat: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="143582" href="/d/html/143582.html" rel="external">see "Nirogacestat: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58895133"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ogsiveo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58879553"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Gamma Secretase Inhibitor;</li>
<li>
                        Gamma Secretase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F58898437"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddf2883e-66eb-4c25-a800-dda324b40e60">Desmoid tumors, progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desmoid tumors, progressive: Oral: </b>150 mg twice daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36884323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36884323'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>If dose of nirogacestat is missed or if vomiting occurs following administration, skip dose and resume with next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58898439"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥41 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling; however, no clinically significant differences in nirogacestat pharmacokinetics were observed.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;41 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F58898440"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild hepatic impairment: There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate hepatic impairment: There are no dosage adjustments provided in the manufacturer’s labeling; however, mean AUC increased by up to 16% and mean C<sub>max</sub> decreased by up to 39% in subjects with moderate hepatic impairment when compared to subjects with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT ≥3 to 5 × ULN (grade 2): Withhold nirogacestat until ALT, AST, or both have resolved to &lt;3 × ULN or baseline; resume nirogacestat at 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT &gt;5 × ULN (grades 3 or 4): Permanently discontinue nirogacestat.</p></div>
<div class="block dot drugH1Div" id="F58898441"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Nirogacestat Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Nirogacestat dosage modification</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">GI toxicity: diarrhea</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">May require management with antidiarrheal medications.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4 (persisting ≥3 days despite maximal medical therapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold nirogacestat until resolved to grade ≤1 or baseline; resume nirogacestat at 100 mg twice daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypophosphatemia (persisting ≥3 days despite maximal replacement therapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold nirogacestat until resolved to grade ≤1 or baseline; resume nirogacestat at 100 mg twice daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypokalemia (despite maximal replacement therapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold nirogacestat until resolved to grade ≤1 or baseline; resume nirogacestat at 100 mg twice daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other adverse reactions (clinically significant)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe;</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Life-threatening;</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Persistent, intolerable grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold nirogacestat until resolved to grade ≤1 or baseline; resume nirogacestat at 100 mg twice daily only after consideration of potential benefit and likelihood of toxicity recurrence.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recurrence of severe or life-threatening adverse reactions following rechallenge at the reduced dose</i>: Permanently discontinue nirogacestat.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58898438"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58887861"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (19%), folliculitis (&lt;15%), dermatologic disorder (hidradenitis suppurativa: &lt;15%), skin carcinoma (nonmelanoma: &lt;15%; including basal cell carcinoma of skin [1%], squamous cell carcinoma of skin [3%]), skin rash (68%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum phosphate (20% to 65%), decreased serum potassium (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (22%), diarrhea (84%; grade 3: 16%), nausea (54%; grade 3: 1%), stomatitis (39%; grade 3: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria (51%), ovarian disease (75%, including amenorrhea, ovarian failure, menopause, and premature menopause; serious: 4%), proteinuria (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (30%), increased serum aspartate aminotransferase (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (54%), headache (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (20%), dyspnea (16%), epistaxis (&lt;15%), flu-like symptoms (&lt;15%), upper respiratory tract infection (17%)</p></div>
<div class="block coi drugH1Div" id="F58872782"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58898411"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Alterations in potassium and phosphate levels may occur during treatment with nirogacestat. In a clinical study, two-thirds of patients experienced decreased phosphate and one-quarter of patients experienced decreased potassium; phosphate &lt;2 mg/dL and grade 3 hypokalemia also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Diarrhea, including severe cases, can occur with nirogacestat treatment. A majority of patients treated with nirogacestat in a clinical study experienced diarrhea; grade 3 events were also observed. Median time to first event of diarrhea was 9 days (range: 2 to 434 days).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: AST or ALT elevations occurred in approximately one-third of nirogacestat-treated patients; grade 3 events were also observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin cancers: Treatment with nirogacestat may result in the occurrence of new nonmelanoma skin cancers (including cutaneous squamous cell carcinoma and basal cell carcinoma).</p></div>
<div class="block foc drugH1Div" id="F58895134"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrobromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ogsiveo: 50 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p></div>
<div class="block geq drugH1Div" id="F58895132"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F59040195"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ogsiveo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $193.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F58898403"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Nirogacestat is available through specialty pharmacies/distributors and various specialty institutions/accounts. Examples from the manufacturer may be found at: https://www.ogsiveo.com/files/download/OGSIVEO_Product_Fact_Sheet_and_Ordering_Guide.pdf.</p></div>
<div class="block adm drugH1Div" id="F58898443"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow tablets whole; do not break, crush, or chew.</p></div>
<div class="block hazard drugH1Div" id="F58898414"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Nirogacestat may cause developmental and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-USP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-USP.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USP.1'])">Ref</a></span>). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F58872781"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Desmoid tumors, progressive:</b> Treatment of progressing desmoid tumors in adults who require systemic treatment.</p></div>
<div class="block mst drugH1Div" id="F58898401"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nirogacestat may be confused with niraparib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58898217"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F58898214"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Nirogacestat. Management: If acid-reducing therapy is required, separate nirogacestat administration from antacids by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bitter Orange: May increase the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Nirogacestat may increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Star Fruit: May increase the serum concentration of Nirogacestat.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F58898413"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;">Grapefruit, Seville oranges, and starfruit may interact with nirogacestat. Management: Avoid concomitant use of nirogacestat with grapefruit products, Seville oranges, and starfruit.</p></div>
<div class="block rep_considerations drugH1Div" id="F58898404"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during therapy and for 1 week after the last dose of nirogacestat.</p>
<p style="text-indent:0em;margin-top:2em;">Nirogacestat may cause ovarian toxicity and impair fertility; impact may depend on multiple factors including duration of therapy and gonadal function at the start of treatment. Monitor for menstrual cycle changes and symptoms of estrogen deficiency (eg, hot flashes, night sweats, vaginal dryness).</p></div>
<div class="block pri drugH1Div" id="F58898405"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies using doses less than the recommended human dose (based on AUC), in utero exposure to nirogacestat may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F58898406"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if nirogacestat is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 week after the last dose of nirogacestat.</p></div>
<div class="block dic drugH1Div" id="F58898442"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit products, Seville oranges, and starfruit.</p></div>
<div class="block mop drugH1Div" id="F58898445"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor LFTs, phosphate, and potassium levels regularly during treatment. Perform dermatologic evaluations at baseline and routinely during treatment. Verify pregnancy status prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs/symptoms of electrolyte disturbances (phosphate, potassium), GI toxicity (diarrhea), ovarian toxicity (changes in menstrual cycle regularity or symptoms of estrogen deficiency [eg, hot flashes, night sweats, vaginal dryness]), and/or nonmelanoma skin cancers. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32716741'])">Ref</a></span>) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F58898416"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nirogacestat is a gamma-secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth. Gamma-secretase inhibitors, such as nirogacestat, impair Notch signaling through selective inhibition of gamma-secretase-mediated cleavage of Notch receptors and in studies have shown to prevent the release of the Notch intracellular domain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36884323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36884323'])">Ref</a></span>).</p></div>
<div class="block phk drugH1Div" id="F58898417"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Poorly soluble at pH ≥6.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1,430 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Serum protein binding: 99.6%, human serum albumin: 94.6%; alpha-1 acid glycoprotein: 97.9%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primary: N-dealkylation via CYP3A4 (85%); secondary: metabolism via CYP3A4, 2C19, 2C9, and 2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 19%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 23 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.5 hours (range: 0.5 to 6.5 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 38%; urine: 17% (&lt;1% as unchanged drug); expired air: 9.7%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 45 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F58898426"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The mean AUC increased by up to 16% and the mean C<sub>max</sub> decreased by up to 39% in subjects with moderate hepatic impairment (Child-Turcotte-Pugh class B or NCI-ODWG group C) when compared to subjects with normal hepatic function.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36884323">
<a name="36884323"></a>Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. <i>N Engl J Med</i>. 2023;388(10):898-912. doi:10.1056/NEJMoa2210140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nirogacestat-drug-information/abstract-text/36884323/pubmed" id="36884323" target="_blank">36884323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nirogacestat-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ogsiveo.1">
<a name="Ogsiveo.1"></a>Ogsiveo (nirogacestat) [prescribing information]. Stamford, CT: SpringWorks Therapeutics, Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Accessed November 30, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 143558 Version 11.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
